CX Institutional Has $689,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

CX Institutional decreased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 42.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,185 shares of the company's stock after selling 3,117 shares during the period. CX Institutional's holdings in Zoetis were worth $689,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank bought a new stake in Zoetis in the fourth quarter valued at $824,321,000. Wellington Management Group LLP lifted its stake in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Sarasin & Partners LLP acquired a new stake in shares of Zoetis during the 1st quarter valued at $339,111,000. GAMMA Investing LLC lifted its holdings in shares of Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after purchasing an additional 1,747,423 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Zoetis in the fourth quarter worth about $196,651,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 2.7%

NYSE ZTS traded down $4.55 on Friday, hitting $164.27. The company's stock had a trading volume of 2,973,481 shares, compared to its average volume of 2,551,303. The firm has a market cap of $73.13 billion, a PE ratio of 30.03, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company's 50-day moving average is $158.26 and its 200 day moving average is $164.09. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the business earned $1.38 EPS. The company's revenue was up 1.4% compared to the same quarter last year. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is 35.91%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.18% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Stifel Nicolaus dropped their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.